country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-165437

Copy Link Print Information

AY 31390

AY 31390 is a potent PDE III inhibitor. AY 31390 increases intracellular cAMP levels by selectively inhibiting the low-Km cAMP-specific PDE III, thereby stabilizing platelets and exerting antithrombotic effects independently of plasma adenosine concentrations. AY 31390 can be used in the study of thrombosis, angina pectoris, cerebral ischemia, and peripheral vascular diseases.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 135124-72-0
分子式: C₁₁H₁₁Br₃N₄O
分子量:454.94

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

AY 31390 構造式

CAS 番号: 135124-72-0

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

^[1]

PDE Ⅲ

Phosphodiesterase (PDE) アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
Platelet	IC₅₀	0.18 μM	Inhibition of arachidonic acid-induced aggregation in human platelets assessed via light transmission measurement following 3-minute pre-incubation with the reagent and 4-minute aggregation measurement. Inhibition of arachidonic acid-induced aggregation in human platelets assessed via light transmission measurement following 3-minute pre-incubation with the reagent and 4-minute aggregation measurement.	1896959
Platelet	IC₅₀	0.21 μM	Inhibition of U46619-induced aggregation in human platelets assessed via light transmission measurement following 3-minute pre-incubation with the reagent and 4-minute aggregation measurement. Inhibition of U46619-induced aggregation in human platelets assessed via light transmission measurement following 3-minute pre-incubation with the reagent and 4-minute aggregation measurement.	1896959
Platelet	IC₅₀	0.54 μM	Inhibition of collagen-induced aggregation in human platelets assessed via light transmission measurement following 3-minute pre-incubation with the reagent and 4-minute aggregation measurement. Inhibition of collagen-induced aggregation in human platelets assessed via light transmission measurement following 3-minute pre-incubation with the reagent and 4-minute aggregation measurement.	1896959
Platelet	IC₅₀	0.43 μM	Inhibition of second-phase epinephrine-induced aggregation in human platelets assessed via light transmission measurement following 3-minute pre-incubation with the reagent and 4-minute aggregation measurement. Inhibition of second-phase epinephrine-induced aggregation in human platelets assessed via light transmission measurement following 3-minute pre-incubation with the reagent and 4-minute aggregation measurement.	1896959
Platelet	IC₅₀	0.20 μM	Inhibition of second-phase ADP-induced aggregation in human platelets assessed via light transmission measurement following 3-minute pre-incubation with the reagent and 4-minute aggregation measurement. Inhibition of second-phase ADP-induced aggregation in human platelets assessed via light transmission measurement following 3-minute pre-incubation with the reagent and 4-minute aggregation measurement.	1896959

体外実験

AY 31390 (3 min pre-incubation; 4 min aggregation assay) exerts a potent inhibitory effect on platelet aggregation induced by multiple agonists in human platelet-rich plasma, with IC₅₀ values ranging from 0.18 μM to 0.54 μM depending on the agonist^[1].
AY 31390 (1 μM; 30 min) reversibly inhibits human platelet aggregation induced by Collagen (HY-NP003) and Arachidonic acid (HY-109590), and its inhibitory activity disappears after washing and resuspension^[1].
AY 31390 (0.25-1 μM; 5 min) exerts an anti-platelet aggregation effect in human platelet-rich plasma (PRP) pretreated with ADA (HY-D0855A), and its inhibitory effect on the Arachidonic acid system is not affected by ADA^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

AY 31390 (0.1-0.50 mg/kg; i.v.; single bolus; 15 min) significantly inhibits white thrombus formation in a rabbit arteriovenous shunt model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

New Zealand rabbits (male, 2.0-2.5 kg)^[1]
Dosage:

0.1 mg/kg; 0.25 mg/kg; 0.50 mg/kg
Administration:

i.v.; single bolus; 15 min
Result:

Reduced white thrombus formation by 28.4%.
Reduced white thrombus formation by 47.1%.
Reduced white thrombus formation by 59.7%.

化学情報

CAS 番号 135124-72-0
分子量 454.94
分子式 C₁₁H₁₁Br₃N₄O
SMILES

O=C1N=C(C)NC(NCC2=CC(Br)=CN=C2)=C1Br.Br
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Patelunas DM, et al. Comparative antithrombotic activities of the phosphodiesterase inhibitors pelrinone (AY-26,768), AY-31,390 and milrinone. Thrombosis research. 1991 Jun 01;62(5):389-400. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ